HK Innoen Esophageal Reflux Disease New Drug K-CAB Approved in Indonesia

HK Innoen K-Cab tablets. [Photo by HK Innoen]

[Asia Economy Reporter Lee Gwan-joo] HK inno.N announced on the 12th that its new drug for gastroesophageal reflux disease, K-CAB (active ingredient: Tegoprazan), has received marketing authorization from the Indonesian Food and Drug Authority (NADFC). This approval marks the fourth overseas country approval for K-CAB, following Mongolia, China, and the Philippines among the 34 countries where it has expanded.

The approved indication in Indonesia is "treatment of non-erosive gastroesophageal reflux disease." The local product name is "TEZA," and it is scheduled to be launched in Indonesia next year. After launch, marketing and distribution will be handled by Kalbe, a major pharmaceutical company in Southeast Asia.

K-CAB is a P-CAB class new drug for gastroesophageal reflux disease, recognized as South Korea's 30th new drug and a blockbuster domestic drug with annual outpatient prescription sales exceeding 100 billion KRW. It is characterized by rapid onset of action within as short as 30 minutes after administration and demonstrated efficacy and safety even with long-term use up to six months. Since its domestic launch in 2019, it has expanded overseas to 34 countries including China, the United States, Canada, Mongolia, India, South Africa, six Southeast Asian countries, 17 Latin American countries, and five Eastern European countries.

The Southeast Asian pharmaceutical market has attracted attention as an emerging market with an average annual growth rate of about 8% from 2015 to 2019. In particular, the Indonesian peptic ulcer drug market size was approximately 170.9 million USD as of last year, the largest in Southeast Asia, and this approval of K-CAB is expected to impact the penetration of the Southeast Asian market.

Kwok Dal-won, CEO of HK inno.N, said, "With the domestic new drug K-CAB consecutively obtaining marketing authorization in the Philippines and Indonesia, we expect to stand out in the Southeast Asian gastroesophageal reflux disease treatment market. We plan to expand our global presence beyond Asia, Latin America, and Southeast Asia to Europe and the Middle East, aiming to enter 100 countries by 2028."

This content was produced with the assistance of AI translation services.